The American Journal of Managed Care recently caught up with Dr. Cliff Goodman, senior vice president and director of the Center for Comparative Effectiveness Research, and discussed how decision makers can best assess value as high-cost treatments hit the market.
“The emergence and proliferation, largely for the good, of new therapies for rare diseases, and even ultra-rare diseases, is challenging how we evaluate health care, challenging how we even look at matters of cost effectiveness,” Goodman said during an interview with AJMC.
Goodman said the 1983 Orphan Drug Act has been “wildly successful” at creating incentives for drugmakers to develop new treatments for rare diseases.
“That has been augmented with very well-timed advances in the science,” he said.
